ArticleInfection and drug resistance2024
Fatal Tracheal and Bronchial Destruction Due to Pulmonary Mucormycosis in a 20-Year-Old with Diabetic Ketoacidosis.
Article in Infection and drug resistance, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Transection of the Right Intermediate Bronchus Caused byInfection and drug resistance · 2026Article
- Clinical characteristics of tracheobronchial mucormycosis: a retrospective analysis of twenty cases.Annals of medicine · 2025Article
- Invasive tracheal mucormycosis complicated by myiasis following tracheostomy in a diabetic patient: A case report.Medical mycology case reports · 2025Article
- Three case reports of pulmonary mucormycosis with a review of the literature.Frontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary mucormycosis is a rare and aggressive invasive fungal infection that predominantly affects immunocompromised individuals, such as those with diabetes mellitus or those undergoing immunosuppressive therapy. This case describes a severe instance of pulmonary mucormycosis resulting in progressive tracheal wall destruction in a young, previously healthy male. A 20-year-old male with a denied history of diabetes mellitus was admitted to a local hospital with abdominal pain for 9 days and diagnosed with acute pancreatitis and diabetic ketoacidosis (DKA). During his stay at the local hospital the patient developed respiratory distress and was transferred to our hospital. Although initially given non-invasive respiratory support and broad-spectrum antibiotics, the patient's condition deteriorated and invasive mechanical ventilation and VV-ECMO were given. Bronchoalveolar lavage fluid (BALF) next-generation sequencing (mNGS) identified Rhizopus species, confirming pulmonary mucormycosis. Aggressive antifungal therapy with amphotericin B was administered, followed by the addition of isavuconazole, but the patient's lesions continued to expand, ultimately leading to fatal tracheal and bronchial wall disruption and subsequent haemorrhage. This case emphasizes the rapid progression and extensive tissue destruction characteristics of pulmonary mucormycosis. Early diagnosis and treatment, especially simultaneous antifungal therapy and appropriate surgical intervention, are crucial for improving the prognosis of such severe cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.